Tildrakizumab maintained a favorable safety profile through 208 weeks in patients with psoriatic arthritis, with no new safety signals reported. Abstracts show that institutions can make internal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback